Navigation Links
Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
Date:7/28/2009

SAN FRANCISCO, July 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call on Tuesday, August 4, 2009 to discuss the Company's second quarter 2009 results and provide a corporate update. Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, senior vice president and chief financial officer and Robert De Jager, M.D., chief medical officer, will host the call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A press release for the second quarter ended June 30, 2009, will be released after markets close on August 4.

To participate in the live call by telephone, please dial 888-515-2880 (United States) or 719-457-2652 (International). In addition, the live conference call is being Webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
2. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
3. Poniard Pharmaceuticals Files Shelf Registration
4. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
5. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
10. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
11. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Heavy-Duty Orbital Shakers today. , Eight New Models Available, ... laboratory applications. These shakers are ideal for load capacities from 35 to ...
(Date:7/17/2017)... ... July 17, 2017 , ... Panitch Schwarze Belisario ... in the BiG (Biomedical Innovation Group) annual meeting in China. , This year’s ... antigen receptor T-cell) therapy, a rapidly developing highly personalized anti-cancer technology that involves ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont Pioneer today announced ... website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is ... enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is building on its ...
(Date:7/16/2017)... PARSIPPANY, N.J. (PRWEB) , ... July 16, 2017 ... ... products, laboratory equipment and analytical instruments announced the launch of its new line ... shakers are ideal for applications that require CO2 and humidity for optimal cell ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):